Oculis SA is a clinical-stage biopharmaceutical company whose mission is to develop novel topical treatments (eye drops) for ophthalmic diseases for both back- and front-of-the-eye in order to improve the sight and lives of patients worldwide.

Products, services, technology

OCS-01 being developed in DME and Post-cataract surgery inflammation;
OCS-02 being developed for Dry Eye;
OCS-03 for back- and front-of-the-eye indications,
OCS-04 and OCS-05 for front-of-the-eye indications

Location
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
    2017
  • Number of employees in Switzerland
    1-9
Key business